Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood filtering technique reveal more about prostate cancer spread?

NCT ID NCT06469710

Knowledge-focused Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study looks at whether a procedure called leukapheresis can collect more circulating tumor cells (CTCs) from the blood than a standard blood draw in men with metastatic prostate cancer. CTCs are cancer cells that break away from the tumor and travel in the bloodstream. The goal is to see which method gives a better sample for learning about the tumor's biology and how the cancer spreads. Participants will provide a small blood sample and undergo leukapheresis, a routine procedure that separates white blood cells (and CTCs) from the rest of the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
leukapheresis (a procedure that separates white blood cells from the rest of the blood to concentrate circulating tumor cells)
What this could lead to
If leukapheresis proves better at capturing circulating tumor cells, it could improve how doctors diagnose and monitor metastatic prostate cancer, and deepen understanding of how the cancer spreads.
What could go wrong
This is an observational study with a small number of participants, so results may not apply broadly. The procedure is generally safe but carries standard risks like discomfort or bruising.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with metastatic prostate cancer with the following specific subject recruitment criteria: 1. Clinical diagnosis of metastatic prostate cancer with tumour stage of T3 or above; 2. Metastatic signs on relevant imaging tests, including CT and MRI, whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI, and prostate specific membrane antigen (PSMA)-targeted PET-CT; 3. After radical prostatectomy for prostate cancer with indication of biochemical recurrence (PSA\>0.2ng/mL); 4. Those with metastatic prostate cancer diagnosed by puncture or postoperative pathology; 5. Previous medical history and treatment history.

Ages

18 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. male, aged 18-75 years; and 2. Evidence of metastasis (positive finding of metastasis on one of the following tests: CT and MRI; whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI; prostate-specific membrane antigen-targeted PET-CT); or clinical diagnosis of metastatic prostate cancer (tumour stage of T3 and above) by pathology of aspiration/surgical biopsy; 3. Good general condition, ECOG score 0-1, able to tolerate leukapheresis; 4. Normal haematological analysis, liver and renal function tests at screening; 5. Subjects (or their legal representatives) can understand the informed consent form. Exclusion Criteria: 1. those who have received systemic combination therapy for tumours within 5 years; 2. those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections 3. those with coagulation disorders, DIC or reduced platelets; 4. those receiving exogenous plasma at the time of the trial;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circulating tumor cell are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Neoplastic Cells, Circulating prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Circulating tumor cell Leukapheresis Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Renji Hospital, Shanghai Jiao Tong University

    RECRUITING

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.